company background image
PCRX logo

Pacira BioSciences NasdaqGS:PCRX Stock Report

Last Price

US$29.22

Market Cap

US$1.4b

7D

-0.2%

1Y

-27.3%

Updated

28 Mar, 2024

Data

Company Financials +

Pacira BioSciences, Inc.

NasdaqGS:PCRX Stock Report

Market Cap: US$1.4b

PCRX Stock Overview

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.

PCRX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance4/6
Financial Health5/6
Dividends0/6

Pacira BioSciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pacira BioSciences
Historical stock prices
Current Share PriceUS$29.22
52 Week HighUS$48.60
52 Week LowUS$25.93
Beta0.76
1 Month Change-2.11%
3 Month Change-13.40%
1 Year Change-27.28%
3 Year Change-58.25%
5 Year Change-25.33%
Change since IPO316.24%

Recent News & Updates

Recent updates

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

Feb 05
Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

Jan 05
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Nov 03
We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Jul 28
Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Jul 07
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Apr 18
Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Dec 28
We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Assessing Pacira BioSciences' Growth Prospects

Oct 20

Pacira BioSciences guides Q3 revenue below consensus

Oct 13

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Sep 27

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Sep 20

Pacira BioSciences records 17.7% sequential growth in August revenue

Sep 13

Pacira BioSciences provides update on July product sales

Aug 10

Pacira BioSciences Q2 2022 Earnings Preview

Aug 02

Pacira BioSciences sees Q2 revenue below consensus

Jul 14

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well

Apr 04
These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well

Pacira BioSciences: Higher Prices On The Horizon

Dec 20

Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects

Nov 29
Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects

Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly

Oct 15
Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly

Pacira BioSciences: Attractive Capital Gain Odds Next 3 Months

Sep 17

Pacira Biosciences' EXPAREL average daily sales more than doubles in May

Jun 08

Pacira Bio's Exparel fails to reach primary endpoint in late-stage STRIDE study

May 26

Shareholder Returns

PCRXUS PharmaceuticalsUS Market
7D-0.2%1.2%0.4%
1Y-27.3%25.8%28.8%

Return vs Industry: PCRX underperformed the US Pharmaceuticals industry which returned 25.8% over the past year.

Return vs Market: PCRX underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is PCRX's price volatile compared to industry and market?
PCRX volatility
PCRX Average Weekly Movement5.3%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: PCRX has not had significant price volatility in the past 3 months.

Volatility Over Time: PCRX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006712Frank Leehttps://www.pacira.com

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product.

Pacira BioSciences, Inc. Fundamentals Summary

How do Pacira BioSciences's earnings and revenue compare to its market cap?
PCRX fundamental statistics
Market capUS$1.35b
Earnings (TTM)US$41.96m
Revenue (TTM)US$674.98m

32.4x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PCRX income statement (TTM)
RevenueUS$674.98m
Cost of RevenueUS$260.93m
Gross ProfitUS$414.05m
Other ExpensesUS$372.10m
EarningsUS$41.96m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.90
Gross Margin61.34%
Net Profit Margin6.22%
Debt/Equity Ratio60.0%

How did PCRX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.